Using CCL21 as an adjunct was associated with increased tumour infiltration by immune cells, improved tumour cell apoptosis, and reduced blood vessel formation in the tumour tissue, but this is yet to be repeated in combination with more recent treatments, such as checkpoint inhibition or MAPK inhibitors. The gene discussed is CCL21; the disease is neoplasm.